|
Market Closed -
Nasdaq
00:00:00 05/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 5.620 USD | -0.88% |
|
-4.58% | -51.76% |
| 08-14 | ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises | MT |
| 08-14 | ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SPRY | Delayed | |
CBOE
| SPRY | Real-time |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bearish | Bearish |
| Resistance | 6.38 | 7.17 | 8.05 |
| Spread/Res. | -11.91% | -21.62% | -30.19% |
| Spread/Supp. | +9.55% | +9.55% | +9.55% |
| Support | 5.13 | 5.13 | 5.13 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- SPRY Stock
- Charts ARS Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
